Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enoblituzumab plus Ipilimumab in Advanced Cancers
NCT02381314Phase 1Completed
- Sponsor
- MacroGenics
- Start
- Mar 2015
- Primary completion
- Nov 2017
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of enoblituzumab in melanoma, non-small cell lung cancer (NSCLC), squamous cell carcinoma of the head and neck (HNSCC) and 10 more, sponsored by MacroGenics. Primary endpoint: Number of participants with adverse events at 1 year. Started Mar 2015; status: completed.
02
Drugs
enoblituzumab
03
Conditions
melanomanon-small cell lung cancer (NSCLC)squamous cell carcinoma of the head and neck (HNSCC)mesotheliomaurothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT02381314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02381314.